SEC Comment Letter for New You, Inc. (CIK 0001372184) — Sep 2, 2021
New You, Inc. (CIK 0001372184)
Date: Sept. 2, 2021 · CIK: 0001372184 · Accession: 0000000000-21-010726
AI Filing Summary & Sentiment
File numbers found in text: 000-52668
Letter
United States securities and exchange commission logo September 2, 2021 John Driscoll Chief Financial Officer New You, Inc. 6351 Yarrow Drive Suite E Carlsbad, CA 92011 Re:New You, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed April 8, 2021 Amendment No.1 to Form 10-Q for the Fiscal Quarter Ended March 31, 2021 Filed May 25, 2021 File No. 000-52668 Dear Mr. Driscoll: We issued comments to you on the above captioned filings on July 16, 2021. As of the date of this letter, these comments remain outstanding and unresolved. We expect you to provide a complete, substantive response to these comments by September 17, 2021. If you do not respond, we will, consistent with our obligations under the federal securities laws, decide how we will seek to resolve material outstanding comments and complete our review of your filings and your disclosure. Among other things, we may decide to release publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filings, consistent with the staff's decision to publicly release comment and response letters relating to disclosure filings it has reviewed. Please contact Kevin Kuhar, Accounting Branch Chief, at (202) 551-3662 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
September 2, 2021
John Driscoll
Chief Financial Officer
New You, Inc.
6351 Yarrow Drive
Suite E
Carlsbad, CA 92011
Re:New You, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2020
Filed April 8, 2021
Amendment No.1 to Form 10-Q for the Fiscal Quarter Ended March 31, 2021
Filed May 25, 2021
File No. 000-52668
Dear Mr. Driscoll:
We issued comments to you on the above captioned filings on July 16, 2021. As of the
date of this letter, these comments remain outstanding and unresolved. We expect you to
provide a complete, substantive response to these comments by September 17, 2021.
If you do not respond, we will, consistent with our obligations under the federal securities
laws, decide how we will seek to resolve material outstanding comments and complete our
review of your filings and your disclosure. Among other things, we may decide to release
publicly, through the agency's EDGAR system, all correspondence, including this letter, relating
to the review of your filings, consistent with the staff's decision to publicly release comment and
response letters relating to disclosure filings it has reviewed.
Please contact Kevin Kuhar, Accounting Branch Chief, at (202) 551-3662 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences